The Responsibility to Recontact Research Participants after Reinterpretation of Genetic and Genomic Research Results

The Responsibility to Recontact Research Participants after Reinterpretation of Genetic and Genomic Research Results

Bombard Y, Brothers KB, Fitzgerald-Butt S, et al. Am J Hum Genet. 2019 Apr 4;104(4):578-595. Abstract The evidence base supporting genetic and genomic sequence-variant interpretations is continuously evolving. An inherent consequence is that a variant’s clinical significance might be reinterpreted over time as new evidence emerges regarding

Read more

Draft guidance : Considerations for the Inclusion of Adolescent Patients in Adult Oncology Clinical Trials

Draft guidance :  Considerations for the Inclusion of Adolescent Patients in Adult Oncology Clinical Trials

The purpose of this guidance is to provide the pharmaceutical industry, clinical investigators, and institutional review boards (IRBs) with information to facilitate the inclusion of adolescent patients (for purposes of this guidance defined as ages 12 to 17) in relevant adult oncology clinical trials. FDA recommends the

Read more